What's Driving TrivarX Ltd (ASX:TRI) Shares Higher Today?

Sonal Goyal

03 November 2026 03:09 PM AEDT

What's Driving TrivarX Ltd (ASX:TRI) Shares Higher Today?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

TrivarX shares rose 20.00% to $0.012 in the 3 November 2026 trading session, while the S&P/ASX 200 gained 0.14%.
The quarterly report, dated 30 October 2026, says first participant enrolment in the Stabl-Im study is targeted for Q1 CY27.
Cash at bank was A$1.96 million at 30 September 2026.

During the Trading session on 3 November 2026, TrivarX Ltd (ASX:TRI) shares rose 20.00% to $0.012. The S&P/ASX 200 (ASX:XJO) was up 0.14%, or 12.50 points, at 8,869.00 at 2:42 pm (GMT+11) on the same day. TrivarX is a Melbourne-based company developing the Stabl-Im platform for clinical use. Its latest update is the quarterly activities report for the three months ended 30 September 2026, released on 30 October 2026.

Clinical development progress

The company said key technical, procedural and operational steps for Stabl-Im are progressing toward a planned Phase 1 clinical evaluation. A clinical feasibility and plasma enrichment study protocol has been advanced, establishing a framework for an initial healthy volunteer study.

Trial preparations

Formal clinical site and principal investigator selection has been completed, and the team has expanded. Investigational product Supply has been secured and received. After quarter end, Syntro Health was appointed to prepare and test the product for trial participants.

Pre-clinical work

Pre-clinical studies have commenced, alongside non-clinical work assessing broader potential uses of the platform. The company expects initial results from these studies in Q4 CY26.

Sector context

The S&P/ASX 200 gained 0.14% during the session. The company's report discusses its own development milestones and does not describe broader healthcare sector trends.

Risks

The clinical timetable depends on ethics, regulatory and operational approvals. First participant enrolment is targeted for Q1 CY27 and initial results for Q2 CY27, and both dates could move. Cash at bank of A$1.96 million is the company's stated funding position, and further funding will be needed for later stages of development.

What lies ahead

The next steps are pre-clinical results in Q4 CY26, first participant enrolment in Q1 CY27 and initial clinical study results in Q2 CY27, subject to approvals.

Final Word

TrivarX's quarter focused on preparing for its first clinical study.

FAQs

Q: How did TrivarX shares trade on 3 November 2026?

A: During the trading session, shares rose 20.00% to $0.012, while the S&P/ASX 200 gained 0.14%.

Q: When is first enrolment expected?

A: The company targets first participant enrolment in Q1 CY27, subject to remaining ethics, regulatory and operational requirements.

Q: How much cash did TrivarX have?

A: Cash at bank was A$1.96 million at 30 September 2026, according to the quarterly report.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.